AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort

Launched by CHANGHAI HOSPITAL · Oct 9, 2024

Keywords

ClinConnect Summary

The ESPRIT-AI-2 clinical trial is studying a new way to detect pancreatic cancer, specifically a type called pancreatic ductal adenocarcinoma (PDAC), which is known for being hard to spot early. The researchers are using an artificial intelligence (AI) model that analyzes non-contrast CT scans (a type of imaging test that doesn’t use special dye) to improve the chances of finding this cancer at an early stage when it is more treatable. The main goal of the trial is to see how well this AI can identify early-stage PDAC.

To be eligible for this study, participants should be between the ages of 65 and 74 and have had a non-contrast CT scan for various reasons, like a routine check-up or during a hospital visit. However, those who have been diagnosed with pancreatic cancer or other cancers in the last five years, or who have certain medical conditions that make CT scans unsafe, will not be eligible. Participants in the trial can expect to contribute to important research that could help improve early cancer detection for others in the future. This study is currently recruiting participants, and anyone interested should discuss it with their healthcare provider for more information.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • 1. Individuals undergoing routine non-contrast chest and/or abdominal CT scans for non-pancreatic indications.
• • Exclusion Criteria
• • 1. History of pancreatic cancer;
• • 2. History of thoracic or abdominal surgery;
• • 3. Acute pancreatitis within 6 months;
• • 4. Patients referred for evaluation of suspected or confirmed pancreatic cancer.